<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062967</url>
  </required_header>
  <id_info>
    <org_study_id>PI21/00793</org_study_id>
    <nct_id>NCT05062967</nct_id>
  </id_info>
  <brief_title>Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease</brief_title>
  <official_title>Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimónides Biomedical Research Institute of Córdoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimónides Biomedical Research Institute of Córdoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the prevalence and the clinical impact of&#xD;
      Orthohepevirus C infection in different human populations, and to determine its zoonotic&#xD;
      origin comparing the sequences obtained in both human and animal populations. This is an&#xD;
      ambispective study where Orthohepevirus C infection will be evaluated in four high risk human&#xD;
      population: i) patients with acute hepatitis, ii) patients with positive IgM antibody against&#xD;
      Hepatitis E virus infection with undetectable viral load, iii) HIV infected individuals, and&#xD;
      iv) solid organ transplant recipients. Furthermore, we will analyze three animal populations:&#xD;
      i) suburban rodents, ii) domestic rodents, iii) wild carnivores. Viral sequences identified&#xD;
      in both human and animal populations will be compared to evaluate the zoonotic origin of the&#xD;
      infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To carry out the project a database will be created in electronic format, where the study&#xD;
      team will integrate epidemiological, clinical and laboratory tests data of patients. Data&#xD;
      will be anonymous and coded by a data manager.&#xD;
&#xD;
      Primary objective is to assess the prevalence of Ortho-C infection in patients with acute&#xD;
      hepatitis of no identified origin&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
        1. To evaluate the prevalence and risk factors of Ortho-C infection in patients with solid&#xD;
           organ transplant.&#xD;
&#xD;
        2. To evaluate the prevalence and risk factors of Ortho-C infection in patients with HIV&#xD;
           infection.&#xD;
&#xD;
        3. To assess the presence of Ortho-C infection in patients with the presence of antibodies&#xD;
           (IgM) against HEV and absence of HEV-RNA&#xD;
&#xD;
        4. To evaluate the prevalence of infection by Ortho-C in wild and periurban rodents.&#xD;
&#xD;
        5. To evaluate the prevalence of infection by Ortho-C in domestic rodents and mustelids.&#xD;
&#xD;
        6. To evaluate the prevalence of infection by Ortho-C in wild carnivores&#xD;
&#xD;
        7. To molecularly characterize and evaluate the degree of homology of Ortho-C viral&#xD;
           sequences found in humans and animals&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Existence of Ortho-C infection</measure>
    <time_frame>Yearly, up to three years.</time_frame>
    <description>The presence of Ortho-C infection is defined by:&#xD;
HAOD, TrazHE, OrthoC-Tx and Ortho-CoRIS cohorts: presence of RNA-OrthoC in blood.&#xD;
Ortho-C-Rodent and Ortho-C-Carnivore cohorts: presence of RNA-OrthoC in serum, feces and/or liver tissue&#xD;
Ortho-C-Domestic-Rodent cohort: presence of RNA-OrthoC in feces.</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">3257</enrollment>
  <condition>Hepatitis</condition>
  <condition>Liver Diseases</condition>
  <condition>Acute Hepatitis</condition>
  <condition>Chronic Hepatitis</condition>
  <condition>Liver Disease Chronic</condition>
  <arm_group>
    <arm_group_label>HAOD Cohort</arm_group_label>
    <description>This cohort includes patients with acute hepatitis of unknown origin, meaning its origin could not be determined after screening of (at least) HAV, HAB, HAC, HAE, Epstein-Barr virus and cytomegalovirus. Patients will be recruited in 17 centres nationwide.&#xD;
The research group will receive a 1mL plasma / serum sample from each patient to study the presence of Ortho-C infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OrthoC-Tx Cohort</arm_group_label>
    <description>This cohort includes liver or kidney transplant patients under follow-up. The research group will receive a 1mL plasma / serum sample every year from each patient to study the presence of Ortho-C infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ortho-CoRIS Cohort</arm_group_label>
    <description>This cohort includes VIH positive patients who are in follow-up by the Spanish Network of AIDS Research.&#xD;
The research group will receive a plasma / serum sample every year from each patient to study the presence of Ortho-C infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TrazHE Cohort</arm_group_label>
    <description>This cohort includes patients whose clinical picture is compatible with HAE infection.&#xD;
The presence of Ortho-C infection will be studied in patients with positive IgM for HAE and absence of RNA-HAE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ortho-C-Rodent Cohort</arm_group_label>
    <description>This cohort includes wild rats. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in wild rats (Ortho-C's main reservoir).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ortho-C-Domestic Rodent Cohort</arm_group_label>
    <description>This cohort includes domestic rats and mustelids. Feces and liver samples will be taken in order to determine the prevalence of Ortho-C in domestic rats and mustelids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ortho-C-Carnivore Cohort</arm_group_label>
    <description>This cohort includes 236 wild carnivores that feed off rodents. Carnivores' cause of death is they were run over.&#xD;
Feces, liver and serum samples will be taken to study the transmission of Ortho-C.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Depending on the cohort. Please see &quot;Group and Interventions&quot; section to learn about the&#xD;
        study population in each cohort.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. HAOD cohort (Cohort of patients with acute hepatitis of unknown origin)&#xD;
&#xD;
          -  Patients older than 18 years with acute hepatitis of unknown origin (HAOD)&#xD;
&#xD;
             2. OrthoC-Tx cohort (HEV Screening Cohort in Transplant Patients):&#xD;
&#xD;
          -  Kidney or liver transplant subjects&#xD;
&#xD;
             3. Ortho-CoRIS Cohort (derived from the AIDS Research Network Cohort (CoRIS))&#xD;
&#xD;
          -  HIV-infected patients being monitored by the Spanish AIDS Research Network (RIS)&#xD;
&#xD;
             4. TrazHE Cohort (Traceability cohort of Hepatitis E infections)&#xD;
&#xD;
          -  Patients with the presence of antibodies (IgM) against HEV and absence of HEV-RNA&#xD;
&#xD;
             5. Ortho-C-Rodent Collection:&#xD;
&#xD;
          -  Wild and peri-urban rodents (rats) from different areas of Spain&#xD;
&#xD;
             6. Ortho-C-Domestic Rodent Collection:&#xD;
&#xD;
          -  Domestic rodents and mustelids under follow-up in veterinary clinics of different&#xD;
             Spanish municipalities.&#xD;
&#xD;
             7. Ortho-C-Carnivore Collection:&#xD;
&#xD;
          -  Wild carnivores that eat rodents collected by the research team since 2020 in 4&#xD;
             autonomous communities (Extremadura, Andalusia, Murcia and Castilla la Mancha)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANTONIO RIVERO ROMÁN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Reina Sofía</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ANTONIO RIVERO ROMÁN</last_name>
    <phone>957012421</phone>
    <email>ariveror@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Jerez de La Frontera</name>
      <address>
        <city>Jerez De La Frontera</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>JUAN CARLOS ALADOS ARBOLEDAS</last_name>
    </contact>
    <investigator>
      <last_name>JUAN CARLOS ALADOS ARBOLEDAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>CAROLINA FREYRE CARRILLO</last_name>
    </contact>
    <investigator>
      <last_name>CAROLINA FREYRE CARRILLO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto de Investigacion Sanitaria de Santiago de Compostela</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>ANTONIO AGUILERA GUIRAO</last_name>
    </contact>
    <investigator>
      <last_name>ANTONIO AGUILERA GUIRAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion En Recursos Cinegeticos (Irec)</name>
      <address>
        <city>Ciudad Real</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>JOSE FRANCISCO RUIZ FONS</last_name>
    </contact>
    <investigator>
      <last_name>JOSE FRANCISCO RUIZ FONS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>RAUL CUADRADO MATIAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Facultad de Veterinaria de Cordoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>DAVID CANO TERRIZA</last_name>
    </contact>
    <investigator>
      <last_name>DAVID CANO TERRIZA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Investigacion Biomedica de Cordoba (Fibico)</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>ANTONIO RIVERO ROMAN</last_name>
    </contact>
    <investigator>
      <last_name>ANGELA CAMACHO ESPEJO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ANTONIO RIVERO ROMAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ISABEL MARIA MACHUCA SANCHEZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ANA BELEN PEREZ JIMENEZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Maimonides de Investigacion Biomedica de Cordoba (Imibic)</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>ANA FUENTES LOPEZ</last_name>
    </contact>
    <investigator>
      <last_name>ANA FUENTES LOPEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>GABRIEL REINA GONZALEZ</last_name>
    </contact>
    <investigator>
      <last_name>GABRIEL REINA GONZALEZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Especialidades Virgen de La Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>ISABEL VICIANA RAMOS</last_name>
    </contact>
    <investigator>
      <last_name>ISABEL VICIANA RAMOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Orthohepevirus C</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Liver Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing the results of this study after they are made public.</ipd_description>
    <ipd_time_frame>After study results are published.</ipd_time_frame>
    <ipd_access_criteria>Send access request to principal investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

